Terns Pharmaceuticals, Inc. Accounts Payable Change

Accounts Payable Change of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Accounts Payable Change growth rates and interactive chart.


Highlights and Quick Summary

  • Accounts Payable Change for the quarter ending March 31, 2022 was $-410 Thousand (a -181.03% decrease compared to previous quarter)
  • Year-over-year quarterly Accounts Payable Change decreased by -53.46%
  • Annual Accounts Payable Change for 2021 was $1.73 Million (a -250.7% decrease from previous year)
  • Annual Accounts Payable Change for 2020 was $-1.15 Million (a -258.73% decrease from previous year)
  • Twelve month Accounts Payable Change ending March 31, 2022 was $-891 Thousand (a -151.59% decrease compared to previous quarter)
  • Twelve month trailing Accounts Payable Change decreased by -151.3% year-over-year
Trailing Accounts Payable Change for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$-891 Thousand $1.73 Million $1.25 Million $1.74 Million
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Accounts Payable Change of Terns Pharmaceuticals, Inc.

Most recent Accounts Payable Changeof TERN including historical data for past 10 years.

Interactive Chart of Accounts Payable Change of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Accounts Payable Change for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $-0.41
2021 $0.51 $-0.11 $-0.88 $2.21 $1.73
2020 $0.03 $0.38 $-1.31 $-0.25 $-1.15
2019 $0.72

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.